Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Imunon, Inc. (IMNN : NSDQ)

• Company Description    Imunon Inc. is a fully integrated, clinical stage biotechnology company. It focused on advancing a portfolio of treatments which harness the body's natural mechanisms. The company's lead clinical program includes GEN-1. Imunon Inc., formerly known as Celsion Corporation, is based in LAWRENCEVILLE, N.J. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $3.81 Daily Weekly Monthly 20 Day Moving Average: 64,558 shares Shares Outstanding: 3.07 (millions) Market Capitalization: $11.70 (millions) Beta: 1.94 52 Week High: $41.22 52 Week Low: $2.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.75% -4.59% 12 Week -26.73% -27.91% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 997 LENOX DRIVE SUITE 100 - LAWRENCEVILLE,NJ 08648 USA ph: 609-896-9100 fax: 609-896-2200 investorrelations@imunon.com http://www.imunon.com

• General Corporate Information    Officers Stacy R. Lindborg - President and Chief Executive Officer Michael H. Tardugno - Executive Chairman David Gaiero - Chief Financial Officer Khursheed Anwer - Executive Vice President Donald P. Braun - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117N701 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 3.07 Most Recent Split Date: 8.00 (1.15:1) Beta: 1.94 Market Capitalization: $11.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.75 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.28 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 73.83% vs. Previous Quarter: 37.95% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -501.10 06/30/25 - -405.07 ROA 12/31/25 - - 09/30/25 - -166.84 06/30/25 - -158.41 Current Ratio 12/31/25 - - 09/30/25 - 1.73 06/30/25 - 1.30 Quick Ratio 12/31/25 - - 09/30/25 - 1.73 06/30/25 - 1.30 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 1.67 06/30/25 - 1.09 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©